Maxim Group Reiterates Buy Rating and $9 PT on Intec Pharma (NTEC) Following Ph1 Trial Initiation of CBD/THC Using the Accordion Delivery System
Tweet Send to a Friend
Maxim Group analyst Jason Kolbert reiterates Buy rating and $9 price target on Intec Pharma Ltd. (NASDAQ: NTEC), as the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE